Plain-English translation of NCT06644118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing OL-101, a new type of cancer treatment that uses your own immune cells to fight multiple myeloma. The treatment is designed to recognize and attack cancer cells that have become resistant to standard therapies. Researchers will carefully monitor your safety and how well the medication works to shrink your cancer.
Multiple myeloma can become resistant to current treatments, leaving patients with limited options. This trial is exploring whether this new immune cell therapy can help people whose cancer no longer responds to standard medications.
You likely qualify if…
You likely don't qualify if…
You will receive OL-101 as an infusion, with the dose adjusted based on early safety data from other participants. The trial has two phases: an initial dose-escalation phase where researchers carefully increase doses while monitoring safety, and a dose-expansion phase using the safest effective dose. You will have regular visits for blood tests, scans, and physical exams to assess how the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China